Anti-NFkB p100 / p52 (phospho S865) antibody (ab31474)


  • Product nameAnti-NFkB p100 / p52 (phospho S865) antibody
    See all NFkB p100 / p52 primary antibodies
  • Description
    Rabbit polyclonal to NFkB p100 / p52 (phospho S865)
  • SpecificityThis antibody detects endogenous levels of NFkB p100 / p52 protein only when phosphorylated at Serine 865.
  • Tested applicationsSuitable for: ICC/IF, WB, IHC-P, ELISA, IPmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic phosphopeptide derived from Human NFkB p100/ p52 around the phosphorylation site of Serine 865.

  • Positive control
    • WB: extracts of ovary cancer cells. IHC-P:breast carcinoma tissue.



Our Abpromise guarantee covers the use of ab31474 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesELISA: 1/20000.
    ICC/IF: Use at a concentration of 1 µg/ml.
    IHC-P: 1/50 - 1/100.
    IP: Use at an assay dependent dilution.
    WB: 1/500 - 1/1000. Predicted molecular weight: 54 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.
    • Involvement in diseaseNote=A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant.
      Note=A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT).
      Note=In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions.
    • Sequence similaritiesContains 7 ANK repeats.
      Contains 1 death domain.
      Contains 1 RHD (Rel-like) domain.
    • DomainThe C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.
      The glycine-rich region (GRR) appears to be a critical element in the generation of p52.
    • Post-translational
      While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
      Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.
      Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.
    • Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.
    • Information by UniProt
    • Database links
    • Alternative names
      • CVID10 antibody
      • DNA binding factor KBF2 antibody
      • DNA-binding factor KBF2 antibody
      • H2TF1 antibody
      • Lymphocyte translocation chromosome 10 antibody
      • Lymphocyte translocation chromosome 10 protein antibody
      • Lyt 10 antibody
      • Lyt10 antibody
      • NF kB2 antibody
      • NFKB2 antibody
      • NFKB2_HUMAN antibody
      • Nuclear factor NF kappa B p100 subunit antibody
      • Nuclear factor NF kappa B p52 subunit antibody
      • Nuclear factor NF-kappa-B p52 subunit antibody
      • Nuclear factor of kappa light chain gene enhancer in B cells 2 antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 antibody
      • Oncogene Lyt 10 antibody
      • Oncogene Lyt-10 antibody
      • p105 antibody
      • p49/p100 antibody
      see all

    Anti-NFkB p100 / p52 (phospho S865) antibody images

    • Ab31474, at a dilution of 1/50, staining NFkB p100 / p52 in paraffin embedded human breast carcinoma tissue by Immunohistochemistry.
      Left image: treated with ab31474.
      Right image: treated with the same antibody preincubated with sythesized peptide.
    • All lanes : Anti-NFkB p100 / p52 (phospho S865) antibody (ab31474) at 1/500 dilution

      Lane 1 : Extracts of ovary cancer cells (5-30ug).
      Lane 2 : Extracts of ovary cancer cells (5-30ug). Antibody pre-incubated with synthesized peptide.

      goat-anti-rabbit IgG-AP-conjugate.

      Predicted band size : 54 kDa
    • ICC/IF image of ab31474 stained HepG2 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab31474, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

    References for Anti-NFkB p100 / p52 (phospho S865) antibody (ab31474)

    ab31474 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for your enquiry. The originator had their QC group do IHC and dot blot (DNA) for your questions. The data showed that 1) main staining was in nuclear for both tumor and normal tissues used, and 2) This antibody did not react with mitochon...

    Read More